KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $18.1 million.

  • GoodRx Holdings' Share-based Compensation fell 3132.18% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.7 million, marking a year-over-year decrease of 2543.78%. This contributed to the annual value of $99.0 million for FY2024, which is 552.76% down from last year.
  • GoodRx Holdings' Share-based Compensation amounted to $18.1 million in Q3 2025, which was down 3132.18% from $21.4 million recorded in Q2 2025.
  • In the past 5 years, GoodRx Holdings' Share-based Compensation registered a high of $46.5 million during Q1 2021, and its lowest value of $17.9 million during Q2 2023.
  • For the 5-year period, GoodRx Holdings' Share-based Compensation averaged around $28.6 million, with its median value being $28.8 million (2023).
  • Within the past 5 years, the most significant YoY rise in GoodRx Holdings' Share-based Compensation was 200524.89% (2021), while the steepest drop was 8836.69% (2021).
  • Quarter analysis of 5 years shows GoodRx Holdings' Share-based Compensation stood at $33.3 million in 2021, then dropped by 11.62% to $29.4 million in 2022, then decreased by 2.16% to $28.8 million in 2023, then dropped by 27.17% to $21.0 million in 2024, then fell by 13.56% to $18.1 million in 2025.
  • Its last three reported values are $18.1 million in Q3 2025, $21.4 million for Q2 2025, and $19.2 million during Q1 2025.